Last reviewed · How we verify

NCT05431790

Absorbable Interface Screw Clinical Trial

Status unknown NA Last updated 24 June 2022
What this trial tests

NA trial testing Absorbable interface screws manufactured by Natong Biotechnology in Anterior Cruciate Ligament Rupture in 86 participants. Status unknown.

Timeline
30 July 2022
Primary endpoint
30 May 2023
30 June 2023

Quick facts

Lead sponsorPeking University Third Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment86
Start date30 July 2022
Primary completion30 May 2023
Estimated completion30 June 2023

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 80, any sex, with Anterior Cruciate Ligament Rupture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Validation of the safety and efficacy of absorbable interface screws for clinical use

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Anterior Cruciate Ligament Rupture

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05431790.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing